Diagnosis and management of intestinal Behçet's diseas

Clinical Journal of Gastroenterology

Volumn 7, Issue 3, 2014, Pages 205-212

  Hisamatsu, Tadakazu ^a   Naganuma, Makoto ^a   Matsuoka, Katsuyoshi ^a   Kanai, Takanori ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Adalimumab; Anti TNF mAb; Intestinal Beh ets disease; Trisomy 8

Indexed keywords

ALBUMIN; ALPHA DEFENSIN 1; BETA DEFENSIN 2; C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; GAMMA INTERFERON; HLA B51 ANTIGEN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23 RECEPTOR; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE; PROTEIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; BEHCET DISEASE; BLEEDING; CAPSULE ENDOSCOPY; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM INJURY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; GENE AMPLIFICATION; GENE EXPRESSION; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INTERFERON GAMMA RELEASE ASSAY; INTESTINE TUBERCULOSIS; INTESTINE ULCER; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; MOUTH ULCER; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; THORAX RADIOGRAPHY; TISSUE CULTURE; TRISOMY 8; ANTAGONISTS AND INHIBITORS; BEHCET SYNDROME; COMPLICATION; INTESTINAL DISEASES;

ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; HUMANS; INTESTINAL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903700105     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-014-0488-0     Document Type: Review

References (78)

1. Behçet H. Uber rezidivierende, aphthose, durch ein Virus verursachte Geschwire am Mund, am Auge und an den Genitalen. Dermatol Wochenschr. 1937;105:1152-7.
2. Garton RA, Ghate JV, Jorizzo JL. Behçets disease. In: Harris Jr ED, Budd RC, Genovese MC, Firestein GS, Sargent JS, Sledge CB, editors. Textbook of rheumatology. 7th ed. Philadelphia: Saunders; 2005.
3. Krause I, Weinberger A. Behçets disease. Curr Opin Rheumatol. 2008;20:82-7.
4. Criteria for diagnosis of Behçets disease. International study group for Behçets disease. Lancet. 1990;335:1078-80.
5. Suzuki Kurokawa M, Suzuki N. Behcets disease. Clin Exp Med. 2004;4:10-20.
6. Sakane T, Takeno M, Suzuki N, Inaba G. Behçets disease. N Engl J Med. 1999;341:1284-91.
7. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçets disease. Int J Dermatol. 2003;42:346-51.
8. Brandt LJ, Boley SJ. Intestinal ischemia. In: Feldman M, Friedman LS, Sleisenger MH, editors. Gastrointestinal and liver disease. 7th ed. Philadelphia: Saunders; 2002.
9. Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, et al. Development of consensus statements for the diagnosis and management of intestinal Behçets disease using a modified Delphi approach. J Gastroenterol. 2007;42:737-45.
10. Muto T. Iwayuru "simple ulcer" towa. (Historical review of so called "simple ulcer" of the intestine.) I to Chou. (Stomach Intestine.) 1979;14:739-48. (in Japanese).
11. Hayasaki N, Ito M, Suzuki T, Ina K, Ando T, Kusugami K, et al. Neutrophilic phlebitis is characteristic of intestinal Behçets disease and simple ulcer syndrome. Histopathology. 2004;45:377-83.
12. Cheon JH, Kim ES, Shin SJ, Kim TI, Lee KM, Kim SW, et al. Development and validation of novel diagnostic criteria for intestinal Behçets disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492-9.
13. Lorenzetti ME, Forbes IJ, Roberts-Thomson IC. Oesophageal and ileal ulceration in Behçets disease. J Gastroenterol Hepatol. 1990;5:714-7.
14. Ikezawa K, Kashimura H, Hassan M, Nakahara A, Yanaka A, Matsuzaki Y, et al. A case of Behçets syndrome with esophageal involvement treated with salicylazosulfapyridine and prednisolone. Endoscopy. 1998;30:S52-3.
15. Yasuo M, Miyabayashi H, Okano T, Aoki H, Ichikawa K, Hirose Y. Successful treatment with corticosteroid in a case of Behçets syndrome with multiple esophageal ulcerations. Intern Med. 2003;42:696-9.
16. Yokota K, Hirano M, Akiba H, Adachi D, Takeishi M, Akiyama Y, et al. A case of Behçets disease with esophageal ulcers complicated with systemic sclerosis, chronic hepatitis C, and pancytopenia. Nihon Rinsho Meneki Gakkai Kaishi. 2004;27:164-70.
17. Fujiwara S, Shimizu I, Ishikawa M, Uehara K, Yamamoto H, Okazaki M, et al. Intestinal Behcets disease with esophageal ulcers and colonic longitudinal ulcers. World J Gastroenterol. 2006;12:2622-4.
18. Bottomley WW, Dakkak M, Walton S, Bennett JR. Esophageal involvement in Behçets disease. Is endoscopy necessary? Dig Dis Sci. 1992;37:594-7.
19. Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behçets disease: a single center experience in Korea. J Korean Med Sci. 2009;24:52-6.
20. Chang DK, Kim JJ, Choi H, Eun CS, Han DS, Byeon JS, et al. Double balloon endoscopy in small intestinal Crohns disease and other inflammatory diseases such as cryptogenic multifocal ulcerous stenosing enteritis (CMUSE). Gastrointest Endosc. 2007;66:S96-8.
21. Gubler C, Bauerfeind P. Intestinal Behçets disease diagnosed by capsule endoscopy. Endoscopy. 2005;37:689.
22. Hamdulay SS, Cheent K, Ghosh C, Stocks J, Ghosh S, Haskard DO. Wireless capsule endoscopy in the investigation of intestinal Behçets syndrome. Rheumatology (Oxford). 2008;47:1231-4.
23. Neves FS, Fylyk SN, Lage LV, Ishioka S, Goldenstein-Schainberg C, Sakai P, et al. Behçets disease: clinical value of the video capsule endoscopy for small intestine examination. Rheumatol Int. 2009;29:601-3.
24. Chong VF, Pathmanathan R. Familial Behçets syndrome with intestinal involvement-case reports and a review of the literature. Ann Acad Med Singapore. 1993;22:807-10.
25. Kobayashi T, Sudo Y, Okamura S, Ohashi S, Urano F, Hosoi T, et al. Monozygotic twins concordant for intestinal Behçets disease. J Gastroenterol. 2005;40:421-5.
26. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçets disease susceptibility loci. Nat Genet. 2010;42:703-6.
27. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçets disease. Nat Genet. 2010;42:698-702.
28. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcets disease. Ann Rheum Dis. 2013;72:1510-6.
29. Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, et al. Identification of a susceptibility locus in STAT4 for Behçets disease in Han Chinese in a genome-wide association study. Arthr Rheum. 2012;64:4104-13.
30. Ahn JK, Cha HS, Lee J, Jeon CH, Koh EM. Correlation of DEFA1 gene copy number variation with intestinal involvement in Behcets disease. J Korean Med Sci. 2012;27:107-9.
31. Takada H, Nomura A, Ishimura M, Ichiyama M, Ohga S, Hara T. NEMO mutation as a cause of familial occurrence of Behçets disease in female patients. Clin Genet. 2010;78:575-9.
32. Nara K, Kurokawa MS, Chiba S, Yoshikawa H, Tsukikawa S, Matsuda T, et al. Involvement of innate immunity in the pathogenesis of intestinal Behçets disease. Clin Exp Immunol. 2008;152:245-51.
33. Imamura Y, Kurokawa MS, Yoshikawa H, Nara K, Takada E, Masuda C, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcets disease. Clin Exp Immunol. 2005;139:371-8.
34. Ferrante A, Ciccia F, Principato A, Giardina AR, Impastato R, Peralta S, et al. A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behçets disease. Clin Exp Rheumatol. 2010;28:S27-30.
35. Tada Y, Koarada S, Haruta Y, Mitamura M, Ohta A, Nagasawa K. The association of Behçets disease with myelodysplastic syndrome in Japan: a review of the literature. Clin Exp Rheumatol. 2006;24:S115-9.
36. Ahn JK, Cha HS, Koh EM, Kim SH, Kim YG, Lee CK, et al. Behcets disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology (Oxford). 2008;47:1228-30.
37. Kimura S, Kuroda J, Akaogi T, Hayashi H, Kobayashi Y, Kondo M. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis-Behçets syndrome. Leuk Lymphoma. 2001;42:115-21.
38. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia- associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest. 2004;34:690-700.
39. Hsu HC, Lee YM, Tsai WH, Jiang ML, Ho CH, Ho CK, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology. 2002;63:64-9.
40. Zeng W, Chen G, Kajigaya S, Nunez O, Charrow A, Billings EM, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood. 2004;103:325-32.
41. Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, et al. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet. 2006;79:439-48.
42. Tanaka H, Shimizu N, Tougasaki E, Kawajiri C, Hashimoto S, Takeda Y, et al. Successful treatment by azacitidine therapy of intestinal Behçets disease associated with myelodysplastic syndrome. Int J Hematol. 2013;97:520-4.
43. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behçet disease. J Clin Gastroenterol. 2012;46:e38-45.
44. Sonta T, Araki Y, Koubokawa M, Tamura Y, Ochiai T, Harada N, et al. The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcets disease. J Clin Gastroenterol. 2000;30:195-9.
45. Nakase H, Okazaki K, Kawanami C, Uchida K, Ohana M, Uose S, et al. Therapeutic effects on intestinal Behçets disease of an intravenous drug delivery system using dexamethasone incorporated in lipid emulsion. J Gastroenterol Hepatol. 2001;16:1306-8.
46. Toda K, Shiratori Y, Yasuda M, Enya M, Uematsu T, Shimazaki M, et al. Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behçets disease. J Gastroenterol. 2002;37:844-8.
47. Takada Y, Saigenji K. Is intestinal Behçets disease in fact an enterocolitis or an ulcer disease, and is steroid treatment useful or harmful? J Gastroenterol. 2003;38:1015-6.
48. Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcets disease. Inflamm Bowel Dis. 2012;18:750-7.
49. Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, et al. Efficacy of combination therapy of anti-TNF-a antibody infliximab and methotrexate in refractory entero-Behçets disease. Mod Rheumatol. 2011;21:184-91.
50. Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcets disease. Inflamm Bowel Dis. 2010;16:188-9.
51. Yasui K, Uchida N, Akazawa Y, Nakamura S, Minami I, Amano Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis. 2008;14: 396-400.
52. Sayarlioglu M, Kotan MC, Topcu N, Bayram I, Arslanturk H, Gul A. Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçets disease. Ann Pharmacother. 2004;38: 808-11.
53. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçets syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001;49:725-8.
54. Naganuma M, Iwao Y, Inoue N, Hisamatsu T, Imaeda H, Ishii H, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçets disease. Am J Gastroenterol. 2000;95:2848-51.
55. Iida M, Kobayashi H, Matsumoto T, Okada M, Fuchigami T, Yao T, et al. Postoperative recurrence in patients with intestinal Behc ̧ets disease. Dis Colon Rectum. 1994;37:16-21.
56. Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcets disease. Inflamm Bowel Dis. 2011;17:1594-602.
57. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcets disease during the first five years. Dig Dis Sci. 2013;58:496-503.
58. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçets disease: a case report. Gastroenterology. 2001;120: 995-9.
59. Kram MT, May LD, Goodman S, Molinas S. Behçets ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum. 2003;46:118-21.
60. Lee JH, Kim TN, Choi ST, Jang BI, Shin KC, Lee SB, et al. Remission of intestinal Behçets disease treated with anti-tumor necrosis factor alpha monoclonal antibody (infliximab). Korean J Intern Med. 2007;22:24-7.
61. Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçets disease. Inflamm Bowel Dis. 2008;14:1259-64.
62. Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, et al. Efficacy of infliximab in intestinal Behçets disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833-8.
63. Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçets disease: report of a case. Dis Colon Rectum. 2007;50:672-6.
64. Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behçets disease. Arthr Rheum. 2003;49:599-600.
65. Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr. 2008;46:212-5.
66. Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behc ̧ets disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis. 2009;15:1769-71.
67. Chung SH, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH. Intestinal Behçets disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis. World J Gastroenterol. 2013;19:5389-92.
68. Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçets disease: indication of anti-TNFa monoclonal antibodies. J Gastroenterol. 2014;49:156-62.
69. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the Crohns disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415-22.
70. Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, Ocular Behçet Disease Research Group of Japan, et al. Behçets disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120-30.
71. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315.
72. Maruyama Y, Hisamatsu T, Matsuoka K, Naganuma M, Inoue N, Ogata H, et al. A case of intestinal Behçets disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med. 2012;51:2125-9.
73. Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcets disease. World J Gastroenterol. 2012;18:5771-8.
74. Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, et al. Subgroup analysis of the placebocontrolled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohns disease. J Crohns Colitis. 2013;7:213-21.
75. Van Assche G, Magdelaine-Beuzelin C, DHaens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohns disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861-8.
76. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohns disease: results from a single-centre cohort. Gut. 2009;58:492-500.
77. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, SONIC Study Group, et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med. 2010;362:1383-95.
78. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohns disease. Gastroenterology. 2013;145: 1464-78.